Rigel Pharmaceuticals, Inc. drugs

3 results

  • gavreto

    (Pralsetinib)
    Rigel Pharmaceuticals, Inc.
    GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients aged 12 and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory.
    Medication Details
    Drug Interactions

  • rezlidhia

    (olutasidenib)
    Rigel Pharmaceuticals, Inc.
    REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as confirmed by an FDA-approved test.
    Medication Details
    Drug Interactions

  • tavalisse

    (FOSTAMATINIB)
    Rigel Pharmaceuticals, Inc.
    TAVALISSE is approved for treating thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have not adequately responded to prior treatments.
    Medication Details
    Drug Interactions